Welcome to our dedicated page for Nordicus Partners SEC filings (Ticker: NORD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nordicus Partners Corporation filings document material-event disclosures for a public life sciences holding and business-acceleration company. The company’s Form 8-K reports cover capital-structure actions, including private placements and unregistered sales of restricted common stock under Securities Act exemptions.
The filing record also documents governance actions, including the establishment of board committees and adoption of Audit Committee, Compensation Committee, and Nominating Committee charters. These disclosures describe formal board structure, committee responsibilities, equity issuance terms, investor qualification representations, transfer restrictions, and related regulatory exemptions.
Nordicus Partners Corp (NORD) entered into a financing with Keystone Capital Partners LLC via a $600,000 Convertible Grid Promissory Note on September 10, 2026, for which it received $500,000 in cash. The Note bears 5.0% annual interest and matures on June 10, 2027, with principal due at maturity.
As funding consideration, Nordicus issued 250,000 commitment shares of common stock. Upon and only after an Event of Default and from and after June 10, 2027, the lender may convert principal and accrued interest into common stock at 90% of the 10‑day VWAP, with an additional 5% discount and a $750 fee per conversion if DTC trading becomes chilled and is not cured within ten business days. The Note may be prepaid at 120% of outstanding principal.
Nordicus agreed to file, by November 1, 2026, a resale registration statement for shares issuable upon conversion and granted the lender piggyback registration rights. The Note, commitment shares and any conversion shares were issued as unregistered securities in a private offering relying on Section 4(a)(2) and/or Rule 506(b) of Regulation D, with no underwriters or commissions.
Nordicus Partners Corporation (NORD) reported that its Board of Directors appointed Elizabeth Addonizio as a director effective September 1, 2026, filling the vacancy created by the recent resignation of Andrew Ritter. The company entered into a Director’s Agreement with her providing a $10,000 annual cash retainer and options to purchase 25,000 shares of common stock at $4.09 per share, fully vested on the grant date under the 2024 Stock Incentive Plan. Nordicus describes her as an independent director with 25 years of finance experience in investment banking, private equity, and venture investing, as well as extensive U.S. Navy Reserve leadership experience. A related indemnification agreement and a press release announcing the appointment are included as exhibits.
Nordicus Partners Corporation notified that its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 will be filed late. The company states it could not complete accounting records and schedules in time for its independent auditor to review the financial statements without unreasonable effort and expense. It expects to file the Form 10-Q, including unaudited financial statements, within the permitted 5-day extension and anticipates reporting a net loss of approximately $2,300,00 on revenues of $0 for the quarter.
Nordicus Partners Corporation is a U.S.-listed biotech focused on acquiring and developing Nordic-origin drugs for diseases with unmet medical needs, initially in oral disorders and psoriasis. For the year ended March 31, 2026 it generated no revenue (versus $5,000 a year earlier) and reported a net loss attributable to the company of $4.0 million, or $0.22 per share, driven by higher R&D and corporate expenses.
Operating expenses were $4.37 million, including $1.61 million of research and development across three preclinical programs: Orocidin’s QR-01 for periodontitis, Bio-Convert’s QR-02 for oral leukoplakia, and NoviThera’s QR-04 for psoriasis. QR-01 showed efficacy in dog and rat models and QR-02 received a toxicity waiver and is moving toward GMP production, with both programs anticipating Phase IIa trials in the first half of 2027. NoviThera achieved biological proof of concept in a mouse study.
Liquidity is constrained: cash was only $20,878 at March 31, 2026 after using $4.32 million in operating cash flows, largely offset by $4.34 million raised from equity issuances. The independent auditor cited nominal revenue, recurring losses and an accumulated deficit as raising substantial doubt about Nordicus’s ability to continue as a going concern. Management is seeking additional capital and has applied to uplist its shares to the Nasdaq Capital Market.
Nordicus Partners Corporation reported a governance change involving its board of directors. On July 7, 2026, Andrew J. Ritter resigned from the Board of Directors, effective immediately, and also stepped down from the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
The company states that Mr. Ritter resigned to pursue other time-consuming business opportunities and that his resignation was not the result of any disagreement with Nordicus Partners on matters relating to its operations, policies, or practices. No financial results or major transactions are described in this report.
Nordicus Partners Corporation notified the SEC it could not file its Annual Report on Form 10-K for the fiscal year ended March 31, 2026 on time and expects to file within the 15-calendar-day extension.
The company anticipates reporting a net loss of approximately $346,731 on $0 revenues for the year. The delay reflects the need to complete accounting records and allow the independent auditor to finish the audit.
Nordicus Partners Corporation entered into a material definitive agreement related to a private stock offering, issuing 201,500 restricted shares of common stock at $2.75 per share to five private investors in March and April 2026. On June 23, 2026, the company determined to close this private offering on those terms.
The shares were issued without SEC registration, relying on exemptions under Section 4(a)(2) of the Securities Act, Rule 506(b) and (c) of Regulation D, and Regulation S for non-U.S. persons. No underwriters or agents were involved, no underwriting discounts or commissions were paid, and the securities carry transfer restrictions and a legend noting they are not registered and cannot be resold without registration or a valid exemption.
Nordicus Partners Corporation reported another pre-revenue quarter for the three months ended December 31, 2025, as it continues to build a portfolio of preclinical Nordic life sciences companies. Revenue was $0 compared with small related-party revenues in the prior year.
The company posted a net loss attributable to Nordicus of $1.23 million for the quarter and $3.95 million for the nine months, driven mainly by officer compensation, professional fees, and $1.32 million in research and development expenses over nine months. Comprehensive income for the nine months was positive $0.92 million, helped by $4.88 million in foreign currency translation gains.
At December 31, 2025, Nordicus held $189,297 in cash and total assets of $75.9 million, largely in goodwill and in-process R&D from acquisitions of Orocidin and Bio-Convert. Accumulated deficit reached $50.7 million, and management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing.
During the nine months, Nordicus raised about $3.9 million through private issuances of 1.69 million restricted shares, and subsequently raised $1.5 million from 547,036 shares at $2.75 per share. It also repurchased 57,642 shares under a limited buyback program. The portfolio now includes majority stakes in Orocidin, Bio-Convert and NoviThera, all targeting oral health and dermatology indications in preclinical stages.
Nordicus Partners Corporation reports that on November 10, 2025, its board of directors created three standing committees and adopted formal charters for each. The new committees are the Audit Committee, Compensation Committee and Nominating Committee.
The Audit Committee is composed of Kim Mücke (chair), Andrew J. Ritter and Peter Severin, and the board has designated Mr. Mücke as an “audit committee financial expert” under Securities and Exchange Commission rules. The Compensation Committee and Nominating Committee each consist of the same three directors, with different directors serving as chairs. The detailed charters for these committees are filed as exhibits to this report.
Nordicus Partners Corporation reported that in December 2025 it issued a total of 131,000 restricted shares of its common stock to ten private investors at a price of $2.75 per share. On January 5, 2026, the company decided to close this private offering on those terms. The shares were issued in a private placement and have not been registered under U.S. or other applicable securities laws, so they are subject to transfer restrictions and can only be resold under an effective registration statement or a valid exemption.
The company states that it is relying on exemptions from registration under Section 4(a)(2) of the Securities Act, Rule 506(b) and (c) of Regulation D, and Regulation S. The investors were accredited and/or had access to detailed information, there was no general solicitation, no underwriters or agents were involved, and no underwriting discounts or commissions were paid.